Third Harmonic Bio Inc expected to post a loss of 31 cents a share - Earnings Preview

Third Harmonic Bio

09/05/2025 17:24

Third Harmonic Bio Inc THRD.OQ THRD.O is expected to show no change in quarterly revenue when it reports  results on August 6 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Third Harmonic Bio Inc is for a loss of 31 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 5.6% in the last three months. ​

Wall Street's median 12-month price target for Third Harmonic Bio Inc is $5.23​, above​ its last closing price of $5.15. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.28
-0.34
-0.48
Missed
-41.2
Sep. 30 2024
-0.30
-0.30
-0.33
Missed
-10.4
Jun. 30 2024
-0.24
-0.27
-0.26
Beat
3.7​
Mar. 31 2024
-0.30
-0.31
-0.20
Beat
35.3
​​Dec. 31 2023
-0.31
-0.17
Beat
45.2
Sep. 30 2023
-0.27
-0.27
-0.19
Beat
29.6​
Jun. 30 2023
-0.30
-0.30
-0.19
Beat
36.7
Mar. 31 2023
-0.35
-0.35
-0.40
Missed
-14.3

This summary was machine generated May 9 at 16:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)